Literature DB >> 27956199

The path to successful commercialization of cell and gene therapies: empowering patient advocates.

Gerhard Bauer1, Mohamed Abou-El-Enein2, Alastair Kent3, Brian Poole4, Miguel Forte5.   

Abstract

Often, novel gene and cell therapies provide hope for many people living with incurable diseases. To facilitate and accelerate a successful regulatory approval and commercialization path for effective, safe and affordable cell and gene therapies, the involvement of patient advocacy groups (PAGs) should be considered early in the development process. This report provides a thorough overview of the various roles PAGs play in the clinical translation of cell and gene therapies and how they can bring about positive changes in the regulatory process, infrastructure improvements and market stability.
Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  affordability; cell and gene therapies; clinical trials commercialization; patient advocacy; regulation; reimbursement

Mesh:

Year:  2016        PMID: 27956199     DOI: 10.1016/j.jcyt.2016.10.017

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  6 in total

Review 1.  Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.

Authors:  Gerhard Bauer; Magdi Elsallab; Mohamed Abou-El-Enein
Journal:  Stem Cells Transl Med       Date:  2018-07-31       Impact factor: 6.940

Review 2.  The impact of COVID-19 on the cell and gene therapies industry: disruptions, opportunities, and future prospects.

Authors:  Tingting Qiu; Yitong Wang; Shuyao Liang; Ru Han; Mondher Toumi
Journal:  Drug Discov Today       Date:  2021-04-20       Impact factor: 7.851

3.  Evidence generation and reproducibility in cell and gene therapy research: A call to action.

Authors:  Mohamed Abou-El-Enein; Aris Angelis; Frederick R Appelbaum; Nancy C Andrews; Susan E Bates; Arlene S Bierman; Malcolm K Brenner; Marina Cavazzana; Michael A Caligiuri; Hans Clevers; Emer Cooke; George Q Daley; Victor J Dzau; Lee M Ellis; Harvey V Fineberg; Lawrence S B Goldstein; Stephen Gottschalk; Margaret A Hamburg; Donald E Ingber; Donald B Kohn; Adrian R Krainer; Marcela V Maus; Peter Marks; Christine L Mummery; Roderic I Pettigrew; Joni L Rutter; Sarah A Teichmann; Andre Terzic; Fyodor D Urnov; David A Williams; Jedd D Wolchok; Mark Lawler; Cameron J Turtle; Gerhard Bauer; John P A Ioannidis
Journal:  Mol Ther Methods Clin Dev       Date:  2021-07-21       Impact factor: 6.698

Review 4.  Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers.

Authors:  Tingting Qiu; Shuyao Liang; Yitong Wang; Claude Dussart; Borislav Borissov; Mondher Toumi
Journal:  Front Public Health       Date:  2021-11-25

5.  Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey.

Authors:  Eline van Overbeeke; Brett Hauber; Sissel Michelsen; Kathelijne Peerlinck; Catherine Lambert; Cedric Hermans; Phu Quoc Lê; Michel Goldman; Steven Simoens; Isabelle Huys
Journal:  Haemophilia       Date:  2021-09-01       Impact factor: 4.263

6.  Involving Patient Groups in Drug Research: A Systematic Review of Reasons.

Authors:  Christoph Rach; Jan Lukas; Regina Müller; Matthias Sendler; Peter Simon; Sabine Salloch
Journal:  Patient Prefer Adherence       Date:  2020-03-12       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.